Patients with high ambulatory pulse pressure (APP) or nondipping pattern of circadian BP (nondippers) are at increased risk of cardiovascular disease that may be due to abnormalities in coagulopathy and vascular function. We hypothesized that patients with high APP or nondipper status have an adverse hemostasis profile. Accordingly, we assessed hemorheology (by plasma viscosity and fibrinogen levels), endothelial damage/dysfunction (von Willebrand factor [vWf] and flow-mediated dilatation [FMD]), thrombogenesis (D-dimer), and platelet activation (soluble P-selectin).
hypertensives. 10 The PP has also been shown to independently associate with the presence of coronary artery disease (CAD) in patients undergoing coronary angiography, and also to predict the incidence of restenosis after balloon angioplasty. 11, 12 In addition to the average 24-h BP level, ABPM provides information on the circadian rhythm of BP, which, in health, has a diurnal elevation and a nocturnal decline. Large-scale prospective studies demonstrate a higher cardiovascular morbidity and mortality in hypertensive nondippers (subjects with a blunted circadian nocturnal decrease in BP on the ABPM) than in dippers. 4, [13] [14] [15] . Several cross-sectional studies have also reported more advanced target organ damage in nondippers. 16 -20 The lack of a nocturnal decrease in BP is also present in normotensives and patients with CAD, 15 which in the latter 21 is associated with more silent and night-time cardiac ischemia. 21, 22 The exact mechanisms underlying the link between elevated systolic and diastolic BP, PP, or nondipping pattern of nocturnal BP and cardiovascular risk are unclear but may be related to abnormal hemostasis or endothelial damage/dysfunction. For example, increased plasma viscosity PV) and fibrinogen levels (hemorheologic indices), fibrin D-dimer (an index of thrombogenesis), soluble Pselectin (sP-selectin, marking platelet activation), impaired forearm blood flow after temporary hyperemia (ie, flow-mediated dilatation, FMD), and von Willebrand factor (vWf; indices of endothelial damage/dysfunction) all independently predict cardiovascular outcomes. [23] [24] [25] [26] [27] Furthermore, the endothelium, as the primary target organ for atherosclerosis, is intimately involved in important physiologic functions, such as homeostasis of the coagulation/ fibrinolysis system, such that damage to this tissue contributes to hypertension and thrombosis. 28 We therefore hypothesized a link between elevated ambulatory PP or nondipping pattern of circadian BP and abnormal hemorheology, platelet activation, thrombogenesis, and endothelial damage/dysfunction. Thus, we sought to determine whether or not CAD patients with high 24-h ambulatory PP or nondipping circadian pattern of BP had higher plasma levels of fibrinogen, fibrin D-dimer, vWf, sP-selectin, and PV, as well as a greater degree of impaired brachial artery endothelium-dependent FMD when compared to patients with low 24-h ambulatory PP or normal dipping pattern. We tested our hypothesis in a cohort of subjects with CAD and compared them with healthy age-and sex-matched controls.
Methods
Seventy-three patients with documented and clinically stable CAD (who had either previous history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting [CABG] ) were recruited from our Cardiology and Hypertension Out-Patient clinics. All were on established (and stabilized for Ͼ3 months) on standard secondary prevention therapy (eg, aspirin, ␤-blockers, angiotensin-converting enzyme [ACE] inhibitors, statins) and were in sinus rhythm. Subjects were excluded if they had any of the following criteria: shiftworkers, unstable angina, clinical signs of heart failure, left ventricular ejection fraction (LVEF) Ͻ40%, uncontrolled hypertension (systolic BP Ͼ160 mm Hg or diastolic BP Ͼ95 mm Hg measured in the clinic), secondary hypertension, and obstructive sleep apnea. To provide perspective, data from patients were compared to 35 ageand sex-matched healthy controls, by careful history and examination. These controls were recruited from those attending the hospital for nonacute minor surgical conditions, such as cataract surgery, varicose veins, and hernia surgery, and from members of the hospital staff.
None of the patients or controls had a history of renal or liver disease, malignancy, connective tissue disease, deep vein thrombosis or pulmonary embolism, recent infections, inflammatory disorders, or were taking regular nonsteroidal anti-inflammatory drugs or on anticoagulants. All studies were performed in a quiet clinical laboratory. All subjects were asked to abstain from tobacco and alcoholic and caffeine-containing beverages during the night before the study. The study was approved by the local research ethics committee and all gave written informed consent.
Clinic BP and 24-h Ambulatory BP Measurements
The clinic (or office) BP measurement was performed in the sitting position in accordance to the recommendations of the British Hypertension Society (BHS), using the Omron HEM-705CP BP monitors (OMRON Healthcare Europe, Hoofdoorp, The Netherlands). The average of three BP measurements was obtained. Ambulatory BP monitoring measurements were obtained using the oscillometric SpaceLabs 90207 monitor (Redmond, WA) validated according to the Association for the Advancement of Medical Instrumentation (AAMI) and BHS protocols and recommended for clinical use. 29 The ABPM readings were obtained every 30 min throughout the 24-h monitoring period, and for each subject the data were edited and reduced into 24 consecutive 1-h averages. Mean daytime ABPM BPs were taken as the average of BPs from 7 AM to 11 PM, whereas mean night-time ABPM BPs were taken as the average of BPs from 11 PM to 7 AM. During the monitoring procedure, subjects were encouraged to follow their routine daily activities. The ABPM always began between 10 AM and noon. No other procedures were performed during the day of monitoring. Only the ambulatory BP recordings with a minimum of 80% valid readings obtained within 24 h after monitor were accepted. If these criteria were not met, the patient was asked to repeat the study within 3 days. If the repeat study failed to meet the quality control criteria, the ambulatory BP data were considered unevaluable. All measurements (both ABPM and clinic readings) were performed at the patient's nondominant arm with the appropriate cuff size determined by upper arm circumference (14 cm for 24-to 32-cm upper arm circumference, and 16 cm for Ͼ32-cm upper arm circumference).
Subjects with a mean 24-h ambulatory BP Ͼ135/85 mm Hg were considered hypertensive. 30 The mean arterial pressure (MAP) was calculated using the standard formula: MAP ϭ Diastolic BP ϩ 1/3 (Systolic BP Ϫ Diastolic BP). The white-coat effect on systolic and diastolic BPs were defined as initial clinic BP measurements minus respective daytime mean ambulatory readings. Ambulatory and clinic PP were defined as the arithmetic difference between 24-h mean systolic BP and 24-h mean diastolic BP, and between clinic systolic BP and clinic diastolic BP, respectively. Patients were divided into two groups according to high (equal or above median) or low (below median) values of the corresponding PPs. Based on the difference between the average systolic BP recorded during the day and at night, patients were also categorized into two groups. Patients were classified as nondippers if they had a less than 10% decline in daytime mean systolic BP compared with night-time mean systolic BP. The remaining of the patients was classified as dippers.
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Blood Samples
Blood samples were taken from the patient's dominant arm 10 min after office BP measurements. Samples were immediately placed on ice and within 15 min of collection, citrated plasma was obtained from venous blood by centrifugation at 3000 rpm/1000 g for 20 min at 4°C. Aliquots were stored at Ϫ70°C to allow batch analysis.
The vWf and sP-selectin levels were measured by ELISA using commercial reagents (Dako-Patts, Ely, UK and R&D Systems, Abingdon, UK, respectively). Fibrin D-dimer levels were determined with an ELISA from Agen (Huntingdon, UK). Plasma fibrinogen (in grams per liter) was measured by the modified Clauss technique on a Pacific Hemostasis coagulometer (Huntersville, NC) and reagents were from Alpha Laboratories (Eastleigh, Hants, U.K.). An EDTA sample was analysed by the routine hematology autoanalyzers for PV levels (Coulter viscometer, Luton, Beds, UK). Intra-assay and interassay coefficients of variation for all assays were Ͻ5% and Ͻ10%, respectively.
Echocardiography
Echocardiography was performed on a GE Vingmed Ultrasound, System V (Slough, Berkshire, UK) with a 2.5-to 4-MHz transducer. The left ventricular ejection fraction (LVEF) was assessed by the modified biplane Simpson's method from apical four-and two-chamber views. Patients were lying in the left lateral decubitus position at 45 degrees. The left ventricular mass (LVM) was calculated from the M-mode recordings according to the formula of Devereux and Reichek 31 :
3 ) Ϫ 14 g and was indexed for body surface area (LVMi).
Assessment of FMD
All vasoactive medications were discontinued 24 h before the beginning of this study procedure. Studies were performed in the supine position after at least 15 min of rest in a quiet clinical laboratory. Changes in brachial artery luminal diameter after reactive hyperemia and after sublingual nitroglycerin (endothelium-independent vasodilation, NMD) were examined as previously described. 32 In brief, the luminal diameters were measured as the distance between the anterior to the posterior lumen-intima border. First, the mean of three measurements at rest was obtained as baseline. Then a pneumatic cuff was placed at the level of the midforearm and inflated to 250 to 300 mm Hg for 4.5 min. The second scan was performed 30 to 90 sec after cuff release. The mean of the three maximum diameters formed the posthyperemia diameter. When brachial artery diameter had returned to baseline after about 15 min, scans were repeated before and again at 3.5 min after, one-puff of the sublingual glyceryl trinitrate (400-g spray) to assess NMD). Vasodilation (FMD% and NMD%) was calculated as percentage change in diameter compared with baseline. All scans were performed by a single dedicated operator using 10-MHz vascular probe using high-resolution ultrasound (GE Vingmed Ultrasound, System V) and all images were recorded on super-VHS videotape for later analysis. Interobserver and intraobserver variation was Ͻ10%.
Power Calculations
We based our power calculation on levels of vWf, a molecule known to be increased in cardiovascular disease and also to be predictive of poor prognosis. 25 We hypothesized that patients with high ambulatory PP or nondippers would have levels of vWf at least two-thirds of an SD higher than patients with low ambulatory PP or dippers. To achieve this with a 1-␤ power of 0.80 and P Ͻ .05, at least 58 patients in total are required (ie, at least 29 patients per group). However, as we also compared other hemostatic indices, for additional confidence, we aimed to recruit at least 70 patients.
Statistical Analyses
Categorical variables were expressed as percentage and continuous variables as mean Ϯ SD or as median with interquartile range (IQR) for the skewed data (D-dimer, sP-selectin, and FMD). Correlations were performed by Spearman's method. Stepwise multiple regression analysis was performed with FMD and vWf l as dependent variables with age and BP (only those with a univariate P value of Ͻ .20 were selected) as independent variables. Intergroup comparisons were made using the Pearson 2 test for categorical variables and unpaired t test and oneway ANOVA with Tukey post hoc analysis or the Mann- APP ϭ ambulatory pulse pressure, assessed by ambulatory blood pressure monitoring; AMI ϭ acute myocardial infarction; ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin II receptor blocker; BMI ϭ body mass index; CABG ϭ coronary artery bypass grafting; CCB ϭ calcium channel blocker; HDL ϭ high-density lipoprotein; LVEF ϭ left ventricular ejection fraction; LVM ϭ left ventricular mass; PTCA ϭ percutaneous coronary intervention. Values are mean Ϯ SD, median (IQR), or number of patients (%). P values between patient groups. There were no significant differences between groups or subgroups in height, total cholesterol, HDL cholesterol, serum creatinine, and blood glucose (data not shown).
Whitney U test and Kruskal-Wallis test for continuous data, as appropriate. Multivariate analysis of covariance (ANCOVA) was used to test between-group differences in FMD and hemostatic indices adjusted for age and intergroup differences in clinical factors and 24-h mean BP parameters. Skewed data (Shapiro-Wilks test) were log transformed before multivariate analyses. All statistical analyses were performed using SPSS software, version 11 (SPSS Inc., Chicago, IL). A P value Ͻ .05 was considered statistically significant.
Results
Data obtained from 73 patients and 35 controls was analyzed: clinical and demographic characteristics of these patients are summarized in Table 1 and the overall ABPM and clinic BP data are summarized in Table 2 . Overall, the median (IQR) ambulatory PP was 51 mm Hg (41 to 58 mm Hg); thus 38 patients (52%) were classified as having high ambulatory PP and 35 were in a low ambulatory PP group. Forty-three patients (59%) were classified as nondippers and 30 as dippers. The clinic PP in controls was 54 Ϯ 12 mm Hg. There were no significant differences in demographic and clinical variables between the two ambulatory PP groups and the two dipping pattern groups, except high ambulatory PP patients were significantly older than low ambulatory PP patients, and more dippers had previously undergone CABG compared to nondippers. The groups did not differ in the use of established secondary preventive therapy. All patients were in sinus rhythm and had preserved left ventricular systolic function (ie, LVEF Ͼ50%).
Thrombogenesis, Endothelial Damage/ Dysfunction, and Ambulatory BPs
The hemostatic markers and FMD values of the patients were compared with 35 age-and sex-matched healthy controls ( Table 3) . As expected, [23] [24] [25] [26] [27] [28] 32 all measured indices (except NMD) were significantly abnormal in patients with CAD compared to controls (all P Ͻ .01). However, the differences in vWf (P Ͻ .001) and FMD (P Ͻ .001) were highly significant. In a stepwise multivariate analysis, both these indices were independently associated with the presence of CAD (both P ϭ .04).
Comparisons of high ambulatory PP/low ambulatory PP groups and the nondippers/dippers groups are shown in Table 3 (raw data) and Tables 4 and 5 (multivariate  analysis) . The high ambulatory PP group had significantly higher levels of vWf, D-dimer, fibrinogen, and sP-selectin, (34) .82 27 (63) 11 (37) .028
Values are mean Ϯ SD, median (IQR).
as well as more impaired FMD compared with low ambulatory PP. In addition, FMD, vWf, and D-dimer levels remained as significant associates of high ambulatory PP after further adjustment for age, 24-h mean systolic BP, mean diastolic BP, MAP, dipping pattern status, white coat effects, and LV mass index (Table 4) . However, in multivariate analysis with high/low ambulatory PP as dependent factor, and entering these five indices as independent variables, only vWf (P ϭ .004) was selected. Nondippers had significantly higher levels of vWf, Ddimer, fibrinogen, and sP-selectin, but not PV or FMD compared to dippers (Table 3 ). In addition, vWf, fibrinogen, and sP-selectin remained as significant associates of nondipping after further adjustment for age, 24-h mean systolic BP, mean diastolic BP, and MAP, night-time mean PP, night-time mean systolic BP, and 24-h mean PP, and intergroup differences including hypertensive status (Table 5 ). However, in multivariate analysis with dipping/ nondipping as a dependent factor, and entering these four indices as independent variables, only vWf was selected (P Ͻ .001). Table 6 shows an analysis of the 73 patients when divided into four groups: high ambulatory PP nondippers (group 1), high ambulatory PP dippers (group 2), low ambulatory PP nondippers (group 3) and low ambulatory PP dippers (group 4). The differences among the groups in hemostatic and FMD indices remained significant even after adjustment for ages (all P Ͻ .05). Group 1 (with the most adverse profile) had the lowest FMD and the highest levels vWf, fibrinogen, and sP-selectin. Conversely, group 4 (with the least adverse profile) had the lowest levels of vWf and fibrinogen. The FMD was significantly different overall (ie, a trend), but was no different between individual groups.
Correlations
Modest (arbitrarily defined as r Ͼ0.3) correlations were found between night-time systolic BP and vWf (r ϭ 0.31) and FMD (r ϭ Ϫ0.31) (both P Ͻ .01), 24-h mean PP with sP-selectin (r ϭ 0.34, P ϭ .003) and FMD (r ϭ Ϫ0.36, P ϭ .002) and between daytime PP with vWf (r ϭ 0.33, P ϭ .005). More notable correlations (arbitrarily defined as r Ͼ0.4) were found between vWf and night/day systolic BP ratio, 24-h mean PP, and night-time PP (all P Ͻ .001; Fig. 1 ). Broadly speaking, FMD correlated weakly (r Ͻ 0.3) with many BP indices; that with 24-h PP (r ϭ Ϫ0.24, P ϭ .039) is presented as Fig. 2 .
Similarly, modest (r Ͼ0.3) correlations were found between FMD and PV (r ϭ Ϫ0.31, P ϭ .008), PV and vWf (r ϭ 0.31, P ϭ .007), D-dimer, and vWf (r ϭ 0.32, P ϭ .006) and age with vWf (r ϭ 0.36, P ϭ .002). There were more notable correlations between PV and fibrinogen (r ϭ 0.51, P Ͻ .001), and between fibrinogen and vWf (r ϭ 0.52, P Ͻ .001). The unadjusted correlation between FMD and vWf (r ϭ Ϫ0.45, P Ͻ .001) decreased after adjusting for age, 24-h mean PP, and MAP (r ϭ Ϫ0.34, P ϭ .004), and even further after adjusting for systolic BP night/day ratio (r ϭ Ϫ0.24, P ϭ .047). In combining the 73 patients and the 35 controls, the correlation between vWf and FMD was strong (r ϭ Ϫ0.63, P Ͻ .001) (Fig. 3) . Given the strong mathematical relationships between many of these indices (especially those of BP), many of the correlations are not unexpected [23] [24] [25] and may not add considerably to understanding pathophysiology.
Discussion
Although the prognostic value of one-off clinic systolic and diastolic BP are undoubted, alternative assessments of hypertension, such as one-off or ambulatory PP [1] [2] [3] [4] [5] [6] and dipping/nondipping status, 14 -22 may also be useful. The ABPM seems to be more closely related to target organ damage and to be a better predictor of outcome than clinic or office BP, 33 ambulatory PP may be superior to clinic PP in predicting cardiovascular events, 9 and high PP is an independent predictor of cardiovascular death and myocardial infarction. 1, 2 The predictive value of PP is reportedly independent of systolic BP, diasyolic BP, and MAP, echocardiographic LV mass, white coat hypertension and nondipper status. 3, 4, 6, 8 Our data add possible mechanisms for these relationships: high ambulatory PP associated with higher plasma levels of vWf, D-dimer, and more impaired FMD independent of age, 24-h mean systolic BP, mean diastolic BP, and MAP. Furthermore, the differences in D-dimer, vWf levels, and impaired FMD were also independent of dipping status, white coat effects, and echocardiographic LV mass. Similarly, dipping/nondipping status associated most strongly with vWf, fibrinogen, and sP-selectin levels. Such an abnormal hemostatic profile and impaired endothelial function may contribute in part to the still high rate of recurrent cardiovascular events in patients with CAD despite contemporary secondary preventive therapy.
Epidemiologic data indicate that systolic BP increases continuously with age, whereas diastolic BP levels off between 50 and 60 years, and then begins to decrease steadily beyond the age of 60 years, probably as a conse- quence of large artery stiffness. 7 It is highly plausible that increased PP in our patients with CAD reflects already advanced diseased or stiffened arterial systems that are explained by their chronological age. The fact that the patients with CAD included in this study were clinically stable, and despite already on established (and stabilized for Ͼ3 months) on standard secondary prevention therapy (including statin and those affecting BP), endothelial function and the hemostatic profile was still markedly abnormal. This renders our findings all the more significant, as these secondary preventive therapy may potentially improved endothelial function and plasma hemostatic markers in these patients.
As is well known, PP and systolic BP are highly correlated because both components increase with increases in vascular resistance and large artery stiffness. Also, the general belief is that elevated PP affects coronary outcomes through increased systolic pressure and, thus, afterload and oxygen demand, and diminished coronary perfusion secondary to diastolic pressure reduction and thus myocardial ischemia. However, the fact that our study showed close associations between abnormal hemostatic profile (with a prothrombotic state), impaired systemic endothelial dysfunction, and high ambulatory PP (independent of age, all steady components of the BP, white coat effects and dipping status) suggests that PP per se could be an important pathophysiologic factor that influences cardiovascular outcomes, and is not a mere consequence of aging. Together with the unfavorable hemodynamic profile, PP may further increase the risk for recurrent coronary events in patients with CAD.
Prominent among these mechanisms, by which conventionally assessed hypertension predicts adverse events, is endothelial damage/dysfunction that interferes with the maintenance of vascular tone. 28, 32 Furthermore, high pulsatile blood flow constantly impacting on the atheroma plaque and vessel wall stress may trigger disruption of vulnerable plaques 33 and hence thrombogenesis. 34 Moreover, in patients with existing arterial disease, chronic high pulsatile hemodynamics may promote nonlaminar blood flow that limits the availability of nitric oxide and hence endothelial dysfunction and disturbed haemostasis. 35, 36 Thus, our finding of high vWf associated with high ambulatory PP fits neatly into this picture as this molecule is increased in essential hypertension and CAD, marks endothelial damage, can directly contribute to thrombosis, and predicts adverse events. 25, 28, 38 Ceravolo et al 37 demonstrated that ambulatory PP predicts endothelium-dependent acetylcholine-stimulated forearm blood flow in never-treated hypertensive patients. Our data add to this in that we report an inverse relationship between 24-h ambulatory PP and FMD in patients with CAD. The finding of increased D-dimer in fully adjusted high ambulatory PP is curious and at first sight without a clear mechanism, although previously described in essential hypertension. 40 However, in multivariate analysis, only vWf remained in association with ambulatory PP.
An alternative view of vascular dysfunction is that PP elevation is related with increased large artery stiffness, although it is difficult to establish whether or not this is a cause or consequence of arterial stiffness, endothelial dysfunction, 38 or disturbed homeostasis in the hemostatic systems. Both atherosclerosis and endothelial dysfunction contribute to arterial stiffness 39, 40 and hence increases PP. The latter may promote atherothrombogenesis by changes in sheer stress and impairment of endothelial function 41 and, in the data we currently present, thrombosis. 37 These together may contribute to a vicious circle. High PP leads to vascular endothelial dysfunction and mechanical fa- tigue. That, in turn, promotes atherothrombogenesis, thus increased arterial stiffness, and therefore greater PP.
Several large-scale prospective studies support the concept that disturbed circadian BP with diminished nocturnal BP decrease (nondipping) is associated with a worse prognosis. 4, 13, 14 Cross-sectional studies also reported close association of nondipping with more advanced target organ damage. 16, 17 However, nondipping may not be a true risk factor but a marker of another abnormality that promotes increased cardiovascular risk. Our results show that, after adjustments, nondippers had higher plasma vWf, platelet marker sP-selectin, and fibrinogen compared to dippers, the latter confirming the work of Hermida et al 45 in hypertensive dippers. This suggests that nondipping CAD patients have an abnormal hemostatic profile, which could not be solely explained by more hypertensive, higher PPs and nighttime BP load in these patients.
Furthermore, increased thrombogenicity in nondippers may not be attributable to impaired endothelial function as neither nondipping nor systolic night/day ratio was associated with FMD (although systolic night/day ratio independently associated with vWf). Our data showing no clear relationship between dipping and FMD are in agreement with one study in untreated hypertensive patients that the degree of nocturnal dipping BP was not correlated to metacholine-induced (endothelium-dependent) forearm blood flow. 42 However, nondippers with diminished acetylcholine-induced forearm blood flow has been reported elsewhere. 43 Such contradictory results might be due to different populations studied and the methods used to assess endothelium-dependent vasodilatation.
The mechanisms underlying the relationships between blunted dipping and pathophysiologic end points remain unclear. However, it may be related to impaired autonomic function such as increased sympathetic tone. 44 Nondippers are common in patients with CAD with and without hypertension, 21 and have a greater silent and night-time ischemia and that may be related to an abnormal pattern of autonomic activity, with higher sympathetic and lower parasympathetic modulation. However, whether the increased episodes of myocardial ischemia and abnormal autonomic activity in nondipper CAD patients could also be related to an abnormal hemostatic profile is unknown. A study investigating the relationships between autonomic activity and hemostasis in nondipper CAD patients would be needed to confirm this hypothesis. Although the use of antihypertensive therapy was not significantly different between dippers and nondippers, the large percentage (59%) of nondippers among our patients may suggest the lack of 24-h or night-time therapeutic coverage for systolic BP in nondippers compared to dippers. Even in patients with mild to moderate hypertension, approximately 54% are nondippers for systolic BP. 45, 46 We have previously reported that vWf negatively correlates with FMD in essential hypertension. 32 In our present study in patients with clinically stable CAD, vWf also significantly negatively correlated with FMD. This robust relationship was independent of age, 24-h mean PP and MAP, day and night-time systolic BP, white coat effects, as well as systolic night/day ratio. This further strengthens the view that vWf is a good index for assessing systemic endothelial dysfunction. 28 Other relationships between various hemostatic markers (eg, PV with fibrinogen and vWf with fibrinogen) were as expected. 23, 47 
Potential Limitations
This study is limited by its cross-sectional design and thus the present findings cannot confirm the intuitive causal relationship between high PP and nondipping status with abnormal hemostasis and endothelial dysfunction. Another limitation of this study could be that patients' PP and dipping status was based on 24-h ABPM. A 48-h ABPM may better characterize day to night variation in BP. 16, 46 FIG. 1 Scatterplots of 24-h mean pulse pressure versus plasma von Willebrand factor levels (A) and systolic night/day ratio (B) in patients with CAD. *Adjusted for covariates: age, 24-h mean systolic BP, night-time mean systolic BP, and 24-h mean PP.
We defined nondipper as an individual with a nocturnal decline in systolic BP of Ͻ10%; the use of a different definition based either on MAP or diastolic BP may yield different results. It is of note that there is no consensus in the use of systolic BP or diastolic BP, or MAP for the classification of dippers and nondippers. However, a dayto-night dip in systolic BP of Ͻ10% has been used to characterize individuals as nondippers, and is associated with an increased risk for cardiovascular disease. 13 We also draw attention to the close mathematical relationships 
FIG. 3
Correlation between plasma vWf levels and FMD%. After adjusting for age, 24-h mean systolic BP, mean PP, and MAP in patients with CAD, plasma vWf levels remained correlated with FMD% (r ϭ Ϫ0.34, P ϭ .004), and after adjustment for systolic night/day ratio (r ϭ Ϫ0.244, P ϭ .047).
between many BP indices that may not be pathophysiologic but spurious.
Conclusions and Clinical Implications
The greater degree of blood thrombogenicity and impaired endothelial function in our CAD patients with high PP or nondipping pattern of circadian BP may put them at higher risk for recurrent cardiovascular events compared to patients with normal PP or normal nocturnal BP dip. This is especially the case in nondippers with high PP as this group had 60% higher vWf, 35% higher fibrinogen, and 21% higher soluble P-selectin than the dippers with low PP. All three molecules predict adverse CAD events. 24, 25 Hence, decreasing PP in addition to improving daytime and night-time therapeutic coverage for high systolic BP may offer additional benefits to these patients. Furthermore, the wider use of ABPM may refine the risk stratification of CAD patients, hence targeting treatment to patients who are at most risk. However, we are not aware of evidence to suggest that conventional antihypertensive medications can influence outcome through altering PP or arterial stiffness or through restoring nondipper to dipper status. Therefore, prospective outcome studies and clinical trials are needed to clarify whether the association of high PP and nondipping nocturnal BP with adverse cardiovascular risk is causal or reversible.
